Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Status:
Recruiting
Trial end date:
2024-12-18
Target enrollment:
Participant gender:
Summary
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who
have relapsed after treatment with prior therapies. The protocol is designed to evaluate two
agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and
safety both as single agents and in combination with pomalidomide and dexamethasone. In these
arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one
cycle as single agent followed by the addition of pomalidomide and dexamethasone in
combination for subsequent cycles.
A third arm allows patients to be treated with the FDA approved combination of elotuzumab
plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent
standard of care comparator for the experimental arms.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Multiple Myeloma Research Consortium
Collaborators:
Atrium Health Beth Israel Deaconess Medical Center Bristol-Myers Squibb Dana-Farber Cancer Institute Emory University Hackensack Meridian Health Icahn School of Medicine at Mount Sinai Memorial Sloan Kettering Cancer Center University of Michigan University of Texas Washington University School of Medicine